Start of Phase Ia Clinical Trial with PBTZ169

This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted at one study center in Switzerland.

Four panels (A, B, C and D) of 8 male subjects (6 active and 2 placebo) each undergoing two investigation periods and receiving either single doses of PBTZ169 at increasing dose levels or a matching placebo. Subjects will participate in only one panel. Blocks of 4 subjects (3 under active treatment, 1 under placebo) will be investigated in parallel. Panels A and B are interleaved.

Read More

iM4TB awarded USD 2.45 m for anti-TB drug clinical trials

The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB USD 2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.

Read more here

EPFL tuberculosis non-profit foundation iM4TB receives major grant

EPFL spin-off “Innovative Medicines for Tuberculosis” (iM4TB) has been awarded nearly USD 750,000 by the Bill & Melinda Gates Foundation to develop a breakthrough drug against tuberculosis.

Read more here

EPFL-Nearmedic collaboration

The pharmaceutical company Nearmedic is collaborating with EPFL to participate in the development of a treatment against tuberculosis. The company bought a license covering the use of the molecule in most countries of the former Soviet Union, where multi-resistant strains are prevalent.

Read more here